At least  weeks from prior systemic treatments including investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicities
At least  weeks beyond the last chemotherapy, targeted anticancer agent, major surgery or experimental treatment and recovered from all acute toxicities (? Grade ). Hydroxyurea used to control peripheral blast counts is permitted up to Day  of treatment on study.
Must be at least  weeks since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, any monoclonal antibodies or immunotherapy, and recovered from any clinically significant toxicity experienced during treatment
Subject has not recovered from adverse reactions to prior cancer treatment or procedures (surgery, chemotherapy, immunotherapy, radiation therapy) to CTCAE Grade  or better.
Patients on every ,  or  week systemic therapy programs must be off the treatment program for at least , , or  weeks, respectively, and must have recovered from any clinically significant toxicity experienced; patients on weekly or daily systemic therapy programs and patients receiving radiation must be at least  week since treatment and recovered from any clinically significant toxicity experienced; must be at least  weeks and have recovered from major surgery
At least  weeks beyond prior treatment (chemotherapy, investigational drugs including small molecular inhibitors, endocrine therapy, immunotherapy and/or radiation therapy) or major surgery, and recovered from all acute toxicities to Grade  or less (except alopecia and peripheral neuropathy).
Must be at least  weeks since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, and  weeks since any monoclonal antibodies or immunotherapy, and recovered from any clinically significant toxicity experienced during treatment
Patients must have recovered to less than grade  or to baseline from toxicity of prior chemotherapy or biologic therapy and must not have had major surgery, chemotherapy, radiation or biologic therapy within  weeks prior to beginning treatment; NOTE: Exceptions to this include events not considered to place the subject at unacceptable risk of participation in the opinion of the principal investigator (PI) (e.g., alopecia)
Patients must be at least  weeks from prior systemic therapy, radiation therapy, major surgery, or other investigational therapy, and have recovered from clinically significant toxicities of these prior treatments
At least  weeks beyond treatment (chemotherapy, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities.
At least  weeks beyond treatment (chemotherapy, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities
Patients must be at least  weeks from major surgery, radiation therapy, participation in other investigational trials and must have recovered from clinically significant toxicities of these prior treatments
At least a  week interval should have elapsed between prior surgery, radiation therapy, chemotherapy or any other treatment and the first vaccination; patients should have recovered from surgery and adjuvant treatment
Patients must be at least  weeks from radiation therapy or major surgery and have recovered from prior toxicities
Prior radiation is permitted; however, at least  weeks must have elapsed since the completion of therapy and patients must have recovered from all therapy-associated toxicities to no greater than grade  at the time of registration; patients with symptomatic disease may receive palliative corticosteroids up to  week before initiating therapy
Patients on every , , or  week systemic treatment programs must be off the treatment program at least , , or  week, respectively, and must have recovered from any clinically significant toxicity experienced; patients on weekly or daily systemic treatment programs and patients receiving radiation must be off at least  week and must have recovered from any clinically significant toxicity experienced; must be at least  weeks and have recovered from major surgery
At least  weeks beyond stem cell transplant and  weeks beyond chemotherapy or\n             immunotherapy, major surgery, other experimental treatments, or radiation therapy to\n             the index lesions, and with all acute toxicities from prior therapy resolved to less\n             than Grade  toxicity by NCI CTC version .
Prior radiation therapy must have been completed >  weeks prior to randomization and the patient must be recovered from any acute toxicities associated with radiation therapy; previously irradiated lesions must not be the sole site of disease
Patient has not recovered from clinical and laboratory acute toxicities of chemotherapy, radiotherapy and surgery
Patients must have recovered from acute toxicities from surgery, radiation or chemotherapy; at least  weeks will have elapsed since any prior therapy directed at the malignant tumor
Has had major surgery within  weeks, received radiation therapy within  weeks prior to randomization, or has not recovered (i.e., ? Grade  or at baseline) from AEs due to prior treatment.
At least  weeks since prior chemotherapy, biological therapy, radiation therapy, major surgery, other investigational, or anti-cancer therapy that is considered disease-directed and recovered from prior toxicities to grade - at least  weeks prior to investigational therapy
Patients must be at least  weeks from major surgery, radiation therapy, participation in other investigational trials and must have recovered from clinically significant toxicities of these prior treatments
Patients must have recovered from prior treatment regimens, e.g. surgery, radiation
Must be at least  days since treatment with chemotherapy, biochemotherapy, surgery, radiation, or immunotherapy, and recovered from any clinically significant toxicity experienced during treatment
Minimum of four weeks since any major surgery or since completion of radiation (patients should have adequately recovered from the acute toxicities of any prior therapy)
Must be at least  weeks since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, and  weeks since any monoclonal antibodies or immunotherapy, and recovered from any clinically significant toxicity experienced during treatment
Recovered from prior radiation therapy or surgery
Prior treatment with one to three lines of systemic chemotherapy for locally advanced or metastatic disease and two weeks from any previous anticancer therapy including biologics and recovered from expected toxicity; at least  weeks from major surgery and recovered; at least  weeks from radiation affecting more than % of bone marrow and recovered; and  weeks from other palliative radiation and recovered. No more than  mg/m cumulative dose of doxorubicin is allowed.
Patient has not recovered from clinical and laboratory acute toxicities of chemotherapy, radiotherapy and surgery
Prior hepatic arterial therapy or hepatic radiation therapy; prior surgical resection or ablation of liver metastases is acceptable; patients must be at least one month beyond prior radiotherapy or surgery, and  months beyond chemotherapy and have recovered from all therapy-associated toxicities
